Partial
Mostly Aligned
Patient Risk:
Info
Summary
Only the smoking/age contraindication claim is evaluable from the provided label excerpts and is supported; the other NuvaRing cycle/timing claims are not supported or contradicted because the provided FDA label excerpts do not include the relevant Dosage and Administration guidance.
Category Scores
Accurate Statements
CHCs, including NuvaRing, should not be used by women who are over 35 years of age and smoke.
Boxed Warning: “For this reason, CHCs, including NuvaRing, should not be used by women who are over 35 years of age and smoke.”; Contraindications (4): “NuvaRing is contraindicated… Examples include women who are known to: Smoke, if over age 35…”; Warnings and Precautions (5.1): risk greatest among older (>35 years of age) who also smoke.
Unsupported Statements
NuvaRing is typically used on a monthly cycle.
No relevant FDA label excerpt for cycle schedule (Dosage and Administration) was provided in the prompt.
A NuvaRing is inserted and worn for 3 weeks.
No relevant FDA label excerpt for insertion/wear duration (Dosage and Administration) was provided in the prompt.
A NuvaRing is removed for 1 week.
No relevant FDA label excerpt for ring-free interval duration (Dosage and Administration) was provided in the prompt.
During the 1-week removal interval, a withdrawal bleed usually happens.
No relevant FDA label excerpt for expected bleeding during ring-free interval (Dosage and Administration/Clinical guidance) was provided in the prompt.
After the 1-week break, a new NuvaRing is inserted.
No relevant FDA label excerpt for restart timing (Dosage and Administration) was provided in the prompt.
“Monthly” use of NuvaRing means wearing one ring for 21 days.
No relevant FDA label excerpt mapping “monthly” to 21 days was provided in the prompt.
“Monthly” use of NuvaRing means removing the ring for 7 days.
No relevant FDA label excerpt mapping “monthly” to a 7-day removal interval was provided in the prompt.
“Monthly” use of NuvaRing means starting the next cycle with a new ring afterward.
No relevant FDA label excerpt for cycle transition was provided in the prompt.
If NuvaRing is inserted late, removed early, or if the ring-free interval is longer or shorter than recommended, contraceptive protection can be reduced.
No relevant FDA label excerpt describing missed/late/early use consequences and contraceptive protection impact was provided in the prompt.
If NuvaRing timing is off, backup contraception may be needed depending on how far off-schedule the use is.
No relevant FDA label excerpt describing backup/backup contraception guidance for off-schedule use was provided in the prompt.
Contradictions
Important Omissions
FDA label-supported details for NuvaRing insertion/wear/removal schedule, expected bleeding, and management of late/early insertion/removal (including whether/how backup contraception is recommended).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Info
Only the smoking/age contraindication claim is label-supported by the provided excerpts. The other timing/backup-conception statements cannot be verified against the provided FDA label text and therefore could be inaccurate relative to labeling; however, no direct contradictions with the provided excerpts were found.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Most cycle/timing and off-schedule/backup contraception claims are not evaluable from the provided FDA label excerpts (no Dosage and Administration guidance for these points was included).
Suggested Improvement
Limit claims to label-supported information from the provided excerpts (e.g., the smoking/age contraindication), or provide the relevant FDA label Dosage and Administration text for cycle schedule and missed/off-schedule management before asserting specific timings or backup contraception guidance.